Jade Biosciences, Inc.

NASDAQ:JBIO

Biotechnology

Healthcare
$15.49 -1.25%

-$0.21 today

Market cap
$1.07B
Beta
1.45
P/E (TTM)
-7.4
EPS (TTM)
-$2.24
52W Low $6.67High $28.00

Volume 0.79M

Average 0.83M

JBIO Income Before Tax

Profit after all operating and non-operating items but before income tax.

Jade Biosciences, Inc.NASDAQ: JBIO

Income Before Tax · Q1 FY2026 · quarter ended Mar 2026

Income before tax remains negative

Q1 FY2026 income before tax was -$40.35M, compared with -$2.52M a year earlier. Trailing-twelve-month income before tax was -$129.54M.

Context

  • Income before tax grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly income before tax holds near -$40.35M or moves back toward the trailing-twelve-month quarterly average of -$32.38M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$40.35M-26.6% QoQ
Last fiscal yearDec 2025
-$127.35M-83.0% YoY
LTMMar 2026
-$129.54M-164.7% YoY
Income Before Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-1502.5%——
1 year-83.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Before Tax history

USD · from the income statement

Latest · FY2025
(127.35M) USD
Year-over-year change
-83.0%

Income Before Tax vs competitors

How JBIO compares with its peers on the latest reported figures

  • JBIO's LTM Mar 2026 income before tax of -$129.54M is the 5th highest of the 9 companies compared; the peer median is -$117.26M.
  • Its year-over-year change of -164.7% is the 8th highest of 9, against a peer median of -23.5%.
JBIO Competitors Peer median
Income Before Tax for JBIO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
DWTXDogwood Therapeutics, Inc.LTM Mar 2026-$28.29M -29.8%——
CTNMContineum Therapeutics, Inc. Class A Common StockLTM Mar 2026-$58.44M -17.3%——
ACRSAclaris Therapeutics, Inc.LTM Mar 2026-$69.66M +46.5%—832.6%
ELDNEledon Pharmaceuticals, Inc.LTM Mar 2026-$78.11M -319.6%——
JBIOJade Biosciences, Inc.LTM Mar 2026-$129.54M -164.7%——
KYTXKyverna Therapeutics, Inc.LTM Mar 2026-$156.4M -7.6%——
TRAXFirst Tracks Biotherapeutics IncFY2025-$166.09M -1.5%——
MLTXMoonLake ImmunotherapeuticsLTM Mar 2026-$258.39M -75.2%——
VERAVera Therapeutics, Inc.LTM Jun 2026-$401.89M -84.1%——
Peer median (excluding JBIO) -$117.26M-23.5%—832.6%

Competitors are the stored peer set for JBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue15K68K96K282K0
Gross Profit(15K)(68K)(96K)(282K)0
Gross Margin—————
Research & Development14.99M38.62M64.22M53.19M93.12M
Selling, General & Admin8.02M14.55M17.09M21.13M20.42M
Operating Expenses23.01M53.17M81.31M74.31M113.54M
Depreciation & Amortization15K68K96K282K26K
EBITDA(22.95M)(51.42M)(75.37M)(69.29M)(127.33M)
EBITDA Margin—————
Operating Income(23.02M)(53.24M)(81.41M)(74.6M)(113.54M)
Operating Margin—————
Interest Income65K1.83M5.95M5.04M7.78M
Interest Expense00000
Other Income / Expenses62K1.75M5.94M5.02M(13.81M)
Income Before Tax(22.96M)(51.49M)(75.47M)(69.57M)(127.35M)
Pre-Tax Margin—————
Income Tax Expense3K25K56K55K58K
Net Income(22.96M)(51.51M)(75.52M)(69.63M)(127.41M)
Net Margin—————
EPS (Basic)(32.96)(73.67)(100.38)(85.26)(4.06)
EPS (Diluted)(32.96)(73.67)(100.38)(85.26)(4.06)
Weighted Avg Shares697.44K699.2K752.33K816.63K31.36M
Weighted Avg Shares (Diluted)697.44K699.2K752.33K816.63K31.36M

Jade Biosciences, Inc.

NASDAQ:JBIO

Intrinsic Alpha fair value

Locked

Current Price

$15.49

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.